Baird raised the firm’s price target on Penumbra (PEN) to $345 from $310 and keeps an Outperform rating on the shares. The firm adjusted ratings and price targets in medical technology as part of its 2026 outlook. Baird sees “several potential paths to improved” share performance for the group in 2026.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PEN:
- Penumbra upgraded to Buy from Neutral at Citi
- Penumbra’s Promising Growth: Buy Rating Backed by Strong Portfolio and Technological Advancements
- Penumbra’s Promising Growth: Buy Rating Backed by STORM-PE Trial and Market Expansion
- Penumbra Inc. Reports Strong Q3 Growth Amid Challenges
- Penumbra price target raised to $286 from $285 at Evercore ISI